Hims & Hers (HIMS)
The desk's stance
On our research list, not on the slate.
What the company does
The direct-to-consumer weight-loss ramp: built massive subscriber scale on compounded GLP-1s during shortages, then legitimized its distribution via a March 2026 pact with Novo Nordisk to sell authentic FDA-approved Wegovy and Ozempic on its telehealth platform.
In short: Direct-to-consumer digital healthcare platform. Category: DTC Telehealth & Digital Wellness. Sector: Healthcare, Drug Manufacturers - Specialty & Generic.
G-Street Value and Score
G-Street Value: $22.41, computed Oct 18, 2026 (confidence: low).
How we got there: 50% analyst leg $28.66 (street consensus, after 8% optimism discount) + 50% GainStreet factor value $16.15 (21.91× fwd EPS anchored to healthcare multiples) — analyst and factor views diverge >50%, confidence reduced. 5 analyst targets have no linked source and are shown but not counted; this value will not open a position until they are sourced.
G-Street Score: 40 out of 100 (Weak).
- Top-line growth & guidance: 10 of 32
- Margin power: 8 of 15
- Revenue visibility & quality: 8 of 11
- Profitability & balance sheet: 7 of 24
- Capital allocation & governance: 2 of 6
- Valuation, sentiment & momentum: 5 of 12
Our current thesis
Updated Oct 17, 2026
The thesis
- Top-line revenue accelerated 38.2% YoY to $753.2M, driven by Wegovy partnerships and subscriber additions.
- Active subscriber base expanded to 2.89M, providing substantial high-engagement consumer recurring revenue.
- Category expansion in testosterone therapy and international markets unlocks broad addressable healthcare opportunities.
Risks
- Gross margins compressed to 63.8% due to lower-margin branded GLP-1 distribution and international mix.
- Consecutive deep quarterly EPS misses and GAAP losses demonstrate persistent operational cost headwinds.
- Leveraged balance sheet with $1.55B debt alongside active FTC litigation creates overhang.
What we're watching
- Q3 2026 earnings release on November 9, 2026, targeting $880M-$900M revenue guidance.
- Gross margin trajectory toward the 70% threshold as branded weight-loss volumes scale.
- Resolution and cost impact of FTC litigation and class-action health data inquiries.
Latest
HIMS trades at $28.07, down 4.5% daily and 43.6% over one year, amid gross margin compression and persistent quarterly GAAP losses (-$86.3M in Q2 2026). Although Q2 revenue reaccelerated 38.2% YoY to $753.2M, consecutive severe EPS misses (-$0.37 vs -$0.05) and regulatory scrutiny on compounded GLP-1s remain substantial overhangs. With $1.55B in total debt against $841M in cash and forward P/E at 38.1x, Street sentiment has predominantly converged on Hold.
Key numbers
As of Oct 16, 2026: market cap $6.5B · revenue growth +38.2% year over year · gross margin 69.5% · net margin -5.5% · forward P/E 38.1 · next earnings Nov 9, 2026.
On the Gainz Lab maps
Who it does business with
- Novo Nordisk supplies Hims & Hers — Wegovy via telehealth. Novo partnered with Hims & Hers in March 2026 to distribute authentic Wegovy directly through telehealth, resolving compounded semaglutide disputes.